Heron Therapeutics Inc’s filing revealed that its EVP, Chief Development Officer Forbes William P acquired Company’s shares for reported $27250.0 on Nov 17 ’23. In the deal valued at $1.09 per share,25,000 shares were bought. As a result of this transaction, Forbes William P now holds 79,000 shares worth roughly $0.21 million.
Then, Collard Craig A bought 150,000 shares, generating $137,970 in total proceeds. Upon buying the shares at $0.92, the Chief Executive Officer now owns 186,496 shares.
Before that, Duarte Ira bought 85,000 shares. Heron Therapeutics Inc shares valued at $75,599 were divested by the EVP, Chief Financial Officer at a price of $0.89 per share. As a result of the transaction, Duarte Ira now holds 85,000 shares, worth roughly $0.22 million.
CapitalOne initiated its Heron Therapeutics Inc [HRTX] rating to an Overweight in a research note published on April 23, 2024; the price target was $6. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in mid March has reiterated a ‘”a Buy”‘ rating for it. Guggenheim began covering HRTX with “Buy” recommendation on May 27, 2020. Needham maintained its rating on February 20, 2020. It rated HRTX as “a Buy”.
Price Performance Review of HRTX
On Friday, Heron Therapeutics Inc [NASDAQ:HRTX] saw its stock jump 2.35% to $2.61. Over the last five days, the stock has gained 6.53%. Heron Therapeutics Inc shares have risen nearly 53.53% since the year began. Nevertheless, the stocks have risen 12.02% over the past one year. While a 52-week high of $3.22 was reached on 03/13/24, a 52-week low of $0.50 was recorded on 01/02/24. SMA at 50 days reached $2.71, while 200 days put it at $1.82. A total of 1.34 million shares were traded, compared to the trading of 1.5 million shares in the previous session.
Levels Of Support And Resistance For HRTX Stock
The 24-hour chart illustrates a support level at 2.54, which if violated will result in even more drops to 2.47. On the upside, there is a resistance level at 2.71. A further resistance level may holdings at 2.81. The Relative Strength Index (RSI) on the 14-day chart is 48.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.14%. Stochastics %K at 26.29% indicates the stock is a holding.
The most recent change occurred on January 16, 2019 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $64.
